SEC Form 4 · accession 0001470831-26-000709
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrea Ellis
Director
Period of report
Jul 9, 2026
Accepted (ET)
Jul 13, 2026 · 4:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 9, 2026 | M | 17,167 | $16.75 | A | 39,746 | D | |
| Common Stock | Jul 9, 2026 | S | 17,167 | $84.00 | D | 22,579 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $16.75 | Jul 9, 2026 | M | 17,167 | D | — | Jun 21, 2033 | Common Stock | 17,167 | 17,167 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.
- F21/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.